Daiwa Securities Group Inc. Acquires 3,406 Shares of Hologic, Inc. (NASDAQ:HOLX)

Daiwa Securities Group Inc. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,566 shares of the medical equipment provider’s stock after acquiring an additional 3,406 shares during the period. Daiwa Securities Group Inc.’s holdings in Hologic were worth $2,938,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Innealta Capital LLC bought a new position in Hologic in the 2nd quarter valued at $25,000. iA Global Asset Management Inc. bought a new position in Hologic in the 1st quarter valued at $37,000. Mather Group LLC. bought a new position in Hologic in the 1st quarter valued at $48,000. Massmutual Trust Co. FSB ADV boosted its position in Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the last quarter. Finally, Toth Financial Advisory Corp boosted its position in Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 347 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent research reports. StockNews.com upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Finally, Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Stock Performance

Shares of Hologic stock opened at $81.15 on Friday. The company has a market capitalization of $18.85 billion, a PE ratio of 41.40, a PEG ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $80.20 and its 200 day simple moving average is $76.83.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.93 EPS. On average, research analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 in the last 90 days. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.